Whole-body metabolic activity as a predictor of chemotherapy response in epithelial ovarian cancer
Official title: Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer
Run by University of Tennessee Graduate School of Medicine · NCT07764133 · Data updated 2026-11-12
This study tests whether whole-body metabolic activity can predict how well epithelial ovarian cancer responds to chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 50 (estimated) |
| Sponsor | University of Tennessee Graduate School of Medicine Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Knoxville, Tennessee) |
| Status | Recruiting |
| Started | May 13, 2026 |
| Main results expected | May 13, 2028 |
| Study ends | May 13, 2028 |
| Registry record updated | August 17, 2026 |
| Trial ID | NCT07764133 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women over 18 with suspected epithelial ovarian cancer, planned for surgical debulking and no prior cytotoxic therapy, and with good performance status (ECOG 0-1).
✕Probably not a fit
Patients with poorly controlled diabetes (HbA1c ≥ 9%), or those unable to consent or comply with study procedures, may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study explores how tumor and body-wide metabolism relate to chemotherapy response in women with epithelial ovarian cancer. It uses indirect calorimetry to measure whole-body metabolic activity and compares it with ex vivo tumor metabolic activity. Participants have up to seven study visits aligned with their surgical and chemotherapy schedule, including blood collection for future analyses. The study also looks at how metabolic changes over treatment relate to outcomes and potential effects on healthy tissues and serum metabolites.
Why it matters
Potential benefit: If successful, the study could help predict which patients are most likely to respond to chemotherapy based on metabolic measurements.
How similar studies have gone: Previous research in oncology has used metabolic measures to understand treatment response, but application in this precise whole-body/metabolic axis in ovarian cancer is still evolving.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Women 2. Age \>18 years 3. Suspected of having epithelial ovarian cancer by the provider 4. No prior cytotoxic therapy for ovarian cancer 5. Surgical debulking is planned 6. ECOG performance status 0-1 Exclusion Criteria: 1. Inability to provide voluntary informed consent 2. Received medical intervention for adverse effects of chemotherapy 3. Circumstances and/or medical conditions that would limit compliance with study requirements and protocol, as determined by the principal investigators. 4. Poorly controlled diabetes, hemoglobin A1C ≥9%
Where it's running
-
University of Tennessee Medical Center - Knoxville
Knoxville, Tennessee, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer
This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.
-
[68Ga]BED003 PET imaging to see fibroblast activity in selected cancers
This study tests a PET imaging agent, [68Ga]BED003, to see how well it detects tumors in colorectal, gastric, pancreatic, ovarian, and invasive lobular breast cancers.
-
Dual-target CAR-NK Cells for Peritoneal Cancers of the Ovary, Fallopian Tube, or Pseudoperitoneal Disease
This trial tests a dual-target CAR-NK cell therapy for people with recurrent or hard-to-treat epithelial ovarian, fallopian tube, or primary peritoneal cancer who express two or more specific tumor markers.
-
Dual-Target CAR-NK Cells for Recurrent or Refractory Epithelial Ovarian Cancer
This trial tests EB-DUALNK, a dual-target CAR-NK cell therapy, in adults with recurrent or refractory epithelial ovarian, fallopian tube, or peritoneal cancer to see if it can safely help the cancer shrink or stay controlled.
-
Daphnetin plus TC chemotherapy and targeted maintenance after surgery for stage III–IV epithelial ovarian cancer
This trial tests whether adding daphnetin capsules to standard paclitaxel‑carboplatin chemotherapy and then combining daphnetin with targeted maintenance can help people with stage III–IV epithelial ovarian cancer who had R0 or R1 surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.